Establishing chemoresistance in hematopoietic progenitor cells

Rodney Maze, Helmut Hanenberg, David A. Williams

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

An attractive approach to circumvent chemotherapy-induced myelosuppression is the use of gene-transfer technology to introduce new genetic material into hematopoietic cells. Several pre-clinical studies have demonstrated that increasing the expression of genes encoding proteins that modulate drug resistance in hematopoietic cells provides significant protection against chemotherapy-induced myelosuppression both in vitro and in vivo. Most work in this area has focused on the use of recombinant retroviruses as vectors for the delivery of DNA sequences into hematopoietic stem cells and progenitor cells. Based on these studies, clinical trials are now under way to evaluate the potential use of two gene sequences - multidrug resistance gene 1 and O6-methylguanine DNA methyltransferase. Reducing chemotherapy-induced myelosuppression by increasing the expression of genes that modulate drug resistance via gene transfer into bone marrow cells might allow dose-intensification of chemotherapy, which might result in an improvement in the clinical outcome of patients with high-risk tumors.

Original languageEnglish
Pages (from-to)350-358
Number of pages9
JournalMolecular Medicine Today
Volume3
Issue number8
DOIs
StatePublished - Aug 1997

Fingerprint

Hematopoietic Stem Cells
Drug Therapy
Drug Resistance
Genes
MDR Genes
Technology Transfer
Methyltransferases
Retroviridae
Bone Marrow Cells
Stem Cells
Clinical Trials
Gene Expression
DNA
Neoplasms
Proteins

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine

Cite this

Establishing chemoresistance in hematopoietic progenitor cells. / Maze, Rodney; Hanenberg, Helmut; Williams, David A.

In: Molecular Medicine Today, Vol. 3, No. 8, 08.1997, p. 350-358.

Research output: Contribution to journalArticle

Maze, Rodney ; Hanenberg, Helmut ; Williams, David A. / Establishing chemoresistance in hematopoietic progenitor cells. In: Molecular Medicine Today. 1997 ; Vol. 3, No. 8. pp. 350-358.
@article{b18af8c8ce6a4244b4ae8995c39f7ddb,
title = "Establishing chemoresistance in hematopoietic progenitor cells",
abstract = "An attractive approach to circumvent chemotherapy-induced myelosuppression is the use of gene-transfer technology to introduce new genetic material into hematopoietic cells. Several pre-clinical studies have demonstrated that increasing the expression of genes encoding proteins that modulate drug resistance in hematopoietic cells provides significant protection against chemotherapy-induced myelosuppression both in vitro and in vivo. Most work in this area has focused on the use of recombinant retroviruses as vectors for the delivery of DNA sequences into hematopoietic stem cells and progenitor cells. Based on these studies, clinical trials are now under way to evaluate the potential use of two gene sequences - multidrug resistance gene 1 and O6-methylguanine DNA methyltransferase. Reducing chemotherapy-induced myelosuppression by increasing the expression of genes that modulate drug resistance via gene transfer into bone marrow cells might allow dose-intensification of chemotherapy, which might result in an improvement in the clinical outcome of patients with high-risk tumors.",
author = "Rodney Maze and Helmut Hanenberg and Williams, {David A.}",
year = "1997",
month = "8",
doi = "10.1016/S1357-4310(97)01094-0",
language = "English",
volume = "3",
pages = "350--358",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Establishing chemoresistance in hematopoietic progenitor cells

AU - Maze, Rodney

AU - Hanenberg, Helmut

AU - Williams, David A.

PY - 1997/8

Y1 - 1997/8

N2 - An attractive approach to circumvent chemotherapy-induced myelosuppression is the use of gene-transfer technology to introduce new genetic material into hematopoietic cells. Several pre-clinical studies have demonstrated that increasing the expression of genes encoding proteins that modulate drug resistance in hematopoietic cells provides significant protection against chemotherapy-induced myelosuppression both in vitro and in vivo. Most work in this area has focused on the use of recombinant retroviruses as vectors for the delivery of DNA sequences into hematopoietic stem cells and progenitor cells. Based on these studies, clinical trials are now under way to evaluate the potential use of two gene sequences - multidrug resistance gene 1 and O6-methylguanine DNA methyltransferase. Reducing chemotherapy-induced myelosuppression by increasing the expression of genes that modulate drug resistance via gene transfer into bone marrow cells might allow dose-intensification of chemotherapy, which might result in an improvement in the clinical outcome of patients with high-risk tumors.

AB - An attractive approach to circumvent chemotherapy-induced myelosuppression is the use of gene-transfer technology to introduce new genetic material into hematopoietic cells. Several pre-clinical studies have demonstrated that increasing the expression of genes encoding proteins that modulate drug resistance in hematopoietic cells provides significant protection against chemotherapy-induced myelosuppression both in vitro and in vivo. Most work in this area has focused on the use of recombinant retroviruses as vectors for the delivery of DNA sequences into hematopoietic stem cells and progenitor cells. Based on these studies, clinical trials are now under way to evaluate the potential use of two gene sequences - multidrug resistance gene 1 and O6-methylguanine DNA methyltransferase. Reducing chemotherapy-induced myelosuppression by increasing the expression of genes that modulate drug resistance via gene transfer into bone marrow cells might allow dose-intensification of chemotherapy, which might result in an improvement in the clinical outcome of patients with high-risk tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031406999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031406999&partnerID=8YFLogxK

U2 - 10.1016/S1357-4310(97)01094-0

DO - 10.1016/S1357-4310(97)01094-0

M3 - Article

VL - 3

SP - 350

EP - 358

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 8

ER -